T 细胞受体多样性——一种通用的癌症免疫治疗生物标志物？
TCR diversity - a universal cancer immunotherapy biomarker?
机构信息
University of Wisconsin Carbone Cancer Center, 7007 Wisconsin Institutes for Medical Research, 1111 Highland Avenue, Madison, WI 53705 USA.
出版信息
J Immunother Cancer. 2016 Nov 15;4:69. doi: 10.1186/s40425-016-0175-4. eCollection 2016.
Abstract
Sipuleucel-T was approved as a treatment for men with advanced metastatic, castration-resistant prostate cancer on the basis of improved survival in randomized clinical trials. A major challenge for this therapy, as well as other newer cancer immunotherapy agents, has been to identify markers that can identify patients who benefit from these therapies. In a recent manuscript by Sheikh and colleagues, the investigators evaluated changes in T cell clonality in the peripheral blood and tumors of patients treated with sipuleucel-T using next generation sequencing of T cell receptor Vß CDR3 sequences. Their findings are discussed in the context of this trial and other cancer immunotherapies.
摘要
基于在随机临床试验中提高的生存率，Sipuleucel-T 被批准用于治疗晚期转移性去势抵抗性前列腺癌的男性患者。这种治疗方法以及其他较新的癌症免疫疗法的一个主要挑战是确定可以识别从这些疗法中受益的患者的标志物。在 Sheikh 及其同事的最近一篇论文中，研究人员使用 T 细胞受体 Vβ CDR3 序列的下一代测序评估了接受 sipuleucel-T 治疗的患者外周血和肿瘤中 T 细胞克隆性的变化。他们的研究结果在该试验和其他癌症免疫疗法的背景下进行了讨论。
相似文献
1
TCR diversity - a universal cancer immunotherapy biomarker?T 细胞受体多样性——一种通用的癌症免疫治疗生物标志物？
J Immunother Cancer. 2016 Nov 15;4:69. doi: 10.1186/s40425-016-0175-4. eCollection 2016.
2
T cell receptor repertoire usage in cancer as a surrogate marker for immune responses.癌症中 T 细胞受体库的使用作为免疫反应的替代标志物。
Semin Immunopathol. 2017 Apr;39(3):255-268. doi: 10.1007/s00281-016-0614-9. Epub 2017 Jan 10.
3
3D: diversity, dynamics, differential testing - a proposed pipeline for analysis of next-generation sequencing T cell repertoire data.3D：多样性、动态性、差异测试——一种用于分析下一代测序T细胞受体库数据的提议流程
BMC Bioinformatics. 2017 Feb 27;18(1):129. doi: 10.1186/s12859-017-1544-9.
4
Clonotypic Diversification of Intratumoral T Cells Following Sipuleucel-T Treatment in Prostate Cancer Subjects.前列腺癌患者接受 sipuleucel-T 治疗后肿瘤内 T 细胞的克隆型多样化。
Cancer Res. 2016 Jul 1;76(13):3711-8. doi: 10.1158/0008-5472.CAN-15-3173. Epub 2016 May 23.
5
Cancer-killing CAR therapies gain speed.抗癌嵌合抗原受体疗法提速。
Cancer Discov. 2015 Jan;5(1):7. doi: 10.1158/2159-8290.CD-ND2014-013. Epub 2015 Jan 5.
6
Building on sipuleucel-T for immunologic treatment of castration-resistant prostate cancer.基于 sipuleucel-T 进行免疫治疗去势抵抗性前列腺癌。
Cancer Control. 2013 Jan;20(1):7-16. doi: 10.1177/107327481302000103.
7
Naturally Occurring Genetic Alterations in Proximal TCR Signaling and Implications for Cancer Immunotherapy.天然存在的近端 TCR 信号遗传改变及其对癌症免疫治疗的影响。
Front Immunol. 2021 May 3;12:658611. doi: 10.3389/fimmu.2021.658611. eCollection 2021.
8
Analysis of TCR β CDR3 sequencing data for tracking anti-tumor immunity.用于追踪抗肿瘤免疫的TCR β CDR3测序数据分析。
Methods Enzymol. 2019;629:443-464. doi: 10.1016/bs.mie.2019.08.006. Epub 2019 Sep 5.
9
Helping CAR T cells reach tumors.帮助 CAR T 细胞到达肿瘤。
Cancer Discov. 2015 Jan;5(1):OF6. doi: 10.1158/2159-8290.CD-NB2014-173. Epub 2014 Nov 26.
10
Fine-tuning the effects of T-cell therapy.微调 T 细胞疗法的效果。
Cancer Discov. 2014 Feb;4(2):137. doi: 10.1158/2159-8290.CD-NB2013-184. Epub 2014 Jan 9.
引用本文的文献
1
Spatial TCR clonality and clonal expansion in the in situ microenvironment of non-small cell lung cancer.非小细胞肺癌原位微环境中的空间TCR克隆性与克隆扩增
J Immunother Cancer. 2025 Aug 27;13(8):e012089. doi: 10.1136/jitc-2025-012089.
2
Peripheral Blood TCRβ Repertoire, IL15, IL2 and Soluble Ligands for NKG2D Activating Receptor Predict Efficacy of Immune Checkpoint Inhibitors in Lung Cancer.外周血TCRβ库、白细胞介素15、白细胞介素2以及自然杀伤细胞2D（NKG2D）激活受体的可溶性配体可预测免疫检查点抑制剂在肺癌中的疗效。
Cancers (Basel). 2024 Aug 8;16(16):2798. doi: 10.3390/cancers16162798.
3
Cancer neoantigens as potential targets for immunotherapy.癌症新生抗原作为免疫治疗的潜在靶点。
Clin Exp Metastasis. 2022 Feb;39(1):51-60. doi: 10.1007/s10585-021-10091-1. Epub 2021 May 5.
4
Immune infiltrate diversity confers a good prognosis in follicular lymphoma.免疫浸润多样性预示滤泡性淋巴瘤预后良好。
Cancer Immunol Immunother. 2021 Dec;70(12):3573-3585. doi: 10.1007/s00262-021-02945-0. Epub 2021 Apr 30.
5
From Tumor Mutational Burden to Blood T Cell Receptor: Looking for the Best Predictive Biomarker in Lung Cancer Treated with Immunotherapy.从肿瘤突变负荷到血液T细胞受体：寻找免疫治疗肺癌的最佳预测生物标志物
Cancers (Basel). 2020 Oct 14;12(10):2974. doi: 10.3390/cancers12102974.
6
Analysis of the Heterogeneity of CD4CD25 T Cell TCR CDR3 Repertoires in Breast Tumor Tissues, Lung Metastatic Tissues, and Spleens from 4T1 Tumor-Bearing BALB/c Mice.分析 4T1 荷瘤 BALB/c 小鼠乳腺肿瘤组织、肺转移组织和脾脏中 CD4CD25 T 细胞 TCR CDR3 多样性。
J Immunol Res. 2020 Sep 24;2020:3184190. doi: 10.1155/2020/3184190. eCollection 2020.
7
Partial recovery of disturbed V-J pairing profiles of T-cell receptor in people living with HIV receiving long-term antiretroviral therapy.接受长期抗逆转录病毒治疗的 HIV 感染者中 T 细胞受体 V-J 配对谱紊乱的部分恢复。
Sci China Life Sci. 2021 Jan;64(1):152-161. doi: 10.1007/s11427-020-1718-2. Epub 2020 Jun 18.
8
Tumor mutational burden assessed by targeted NGS predicts clinical benefit from immune checkpoint inhibitors in non-small cell lung cancer.基于靶向 NGS 检测的肿瘤突变负荷可预测非小细胞肺癌免疫检查点抑制剂的临床获益。
J Pathol. 2020 Jan;250(1):19-29. doi: 10.1002/path.5344. Epub 2019 Oct 24.
9
Cheating the Hunger Games; Mechanisms Controlling Clonal Diversity of CD8 Effector and Memory Populations.欺骗饥饿游戏；控制 CD8 效应器和记忆群体克隆多样性的机制。
Front Immunol. 2018 Nov 29;9:2831. doi: 10.3389/fimmu.2018.02831. eCollection 2018.
10
Current landscape and future directions of biomarkers for predicting responses to immune checkpoint inhibitors.预测免疫检查点抑制剂反应的生物标志物的当前现状与未来方向
Cancer Manag Res. 2018 Aug 7;10:2475-2488. doi: 10.2147/CMAR.S167400. eCollection 2018.
本文引用的文献
1
Deep Sequencing of T-cell Receptor DNA as a Biomarker of Clonally Expanded TILs in Breast Cancer after Immunotherapy.深度测序 T 细胞受体 DNA 作为免疫治疗后乳腺癌中克隆扩增 TIL 的生物标志物。
Cancer Immunol Res. 2016 Oct;4(10):835-844. doi: 10.1158/2326-6066.CIR-16-0013. Epub 2016 Sep 1.
2
Clonotypic Diversification of Intratumoral T Cells Following Sipuleucel-T Treatment in Prostate Cancer Subjects.前列腺癌患者接受 sipuleucel-T 治疗后肿瘤内 T 细胞的克隆型多样化。
Cancer Res. 2016 Jul 1;76(13):3711-8. doi: 10.1158/0008-5472.CAN-15-3173. Epub 2016 May 23.
3
Peripheral T cell receptor diversity is associated with clinical outcomes following ipilimumab treatment in metastatic melanoma.外周 T 细胞受体多样性与转移性黑色素瘤患者接受依匹单抗治疗后的临床结局相关。
J Immunother Cancer. 2015 Jun 16;3:23. doi: 10.1186/s40425-015-0070-4. eCollection 2015.
4
PD-1 or PD-L1 Blockade Restores Antitumor Efficacy Following SSX2 Epitope-Modified DNA Vaccine Immunization.PD-1或PD-L1阻断可恢复SSX2表位修饰的DNA疫苗免疫后的抗肿瘤疗效。
Cancer Immunol Res. 2015 Aug;3(8):946-55. doi: 10.1158/2326-6066.CIR-14-0206. Epub 2015 Jun 3.
5
Humoral Immune Response against Nontargeted Tumor Antigens after Treatment with Sipuleucel-T and Its Association with Improved Clinical Outcome.西妥昔单抗治疗后针对非靶向肿瘤抗原的体液免疫反应及其与改善临床结局的关联。
Clin Cancer Res. 2015 Aug 15;21(16):3619-30. doi: 10.1158/1078-0432.CCR-14-2334. Epub 2015 Feb 3.
6
PD-1 blockade induces responses by inhibiting adaptive immune resistance.程序性死亡受体1（PD-1）阻断通过抑制适应性免疫抵抗来诱导反应。
Nature. 2014 Nov 27;515(7528):568-71. doi: 10.1038/nature13954.
7
Activated lymphocyte recruitment into the tumor microenvironment following preoperative sipuleucel-T for localized prostate cancer.术前使用西妥昔单抗治疗局限性前列腺癌后，活化淋巴细胞募集至肿瘤微环境。
J Natl Cancer Inst. 2014 Sep 24;106(11). doi: 10.1093/jnci/dju268. Print 2014 Nov.
8
A transient increase in eosinophils is associated with prolonged survival in men with metastatic castration-resistant prostate cancer who receive sipuleucel-T.在接受 sipuleucel-T 治疗的转移性去势抵抗性前列腺癌男性患者中，嗜酸性粒细胞一过性增加与生存时间延长相关。
Cancer Immunol Res. 2014 Oct;2(10):988-99. doi: 10.1158/2326-6066.CIR-14-0073. Epub 2014 Sep 4.
9
Improved survival with T cell clonotype stability after anti-CTLA-4 treatment in cancer patients.抗 CTLA-4 治疗后肿瘤患者 T 细胞克隆型稳定性改善生存。
Sci Transl Med. 2014 May 28;6(238):238ra70. doi: 10.1126/scitranslmed.3008211.
10
Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy.程序性死亡受体-1（PD-1）、PD-1配体与肿瘤免疫微环境的其他特征与抗PD-1治疗反应的相关性
Clin Cancer Res. 2014 Oct 1;20(19):5064-74. doi: 10.1158/1078-0432.CCR-13-3271. Epub 2014 Apr 8.
Zotero 插件